Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Bempedoic Acid and Ezetimibe in Hypercholesterolemia
NCT01941836Phase 2Completed
- Sponsor
- Esperion Therapeutics
- Start
- Sep 2013
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bempedoic acid in hypercholesterolemia (5 arms), sponsored by Esperion Therapeutics. Primary endpoint: Percent change in calculated low density lipoprotein-cholesterol at 12 weeks. Started Sep 2013; status: completed.
02
Drugs
bempedoic acid
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT01941836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01941836.